Literature DB >> 326391

The chemotherapy of advanced bladder carcinoma.

J B deKernion.   

Abstract

This paper is a summary of the clinical chemotherapy of metastatic or recurrent bladder carcinoma. Mitomycin C, doxorubicin, methotrexate, and 5-fluorouracil appear to have cytotoxic activity against bladder carcinoma when used as single agents, although the reported objective responses to each agent vary greatly. Cyclophosphamide in intermittent high i.v. doses produced an objective response in 4 of 10 patients treated by the author, and other reports suggest that this drug also may have activity against bladder cancer. cis-Dichlorodiammineplatinum is a new drug that also deserves further study.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 326391

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Three-drug combination chemotherapy for advanced urothelial tract carcinoma.

Authors:  S Ohshima; Y Ono; T Fujita; Y Aso
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Chemotherapy in bladder cancer.

Authors: 
Journal:  Br Med J       Date:  1977-12-17

3.  Evaluation of cytostatic drug concentrations in the kidney, bladder wall, and prostate by means of the diffusion chamber technique in dogs.

Authors:  P Porpaczy; C P Schmidbauer; A Georgopoulos; H Rameis; T A Endler
Journal:  Urol Res       Date:  1983

4.  Pharmacokinetics of high-dose methotrexate in dogs. An experimental model with diffusion chambers.

Authors:  P Porpaczy; C P Schmidbauer; A Georgopoulos; A T Endler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 5.  Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.

Authors:  F M Torti; W G Harker
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Adjuvant chemotherapy for invasive bladder cancer.

Authors:  Y Uekado; T Shinka; A Hirano; T Ohkawa
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.

Authors:  A Maru; H Akaza; S Isaka; K Koiso; T Kotake; T Machida; Y Matsumura; Y Nakagami; T Niijima; K Obata
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.

Authors:  T Kotake; M Usami; T Miki; M Kuroda; K Obata; M Osafune; H Fujioka; Y Takasugi
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract--a preliminary report.

Authors:  M H Lee; M T Chen; K K Chen; A T Lin; Y H Lee; L M Lee; Y M Chang; L S Chang; J M Liu; R K Hsieh
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  The chemotherapy of advanced bladder cancer.

Authors:  D W Newling; G Stoter; R Sylvester; M de Pauw
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.